At the news
? NEUTRALIMPACT 4/10 DEFA14A filed Aug 19, 2026 at 21:43 ET
Skye Bioscience filed a DEFA14A to announce the effective date of its previously disclosed 1-for-8 reverse stock split, set for August 24, 2026, as part of its efforts to regain Nasdaq compliance. This filing is a procedural step in the broader transformative acquisition of Redx Pharma, which will fundamentally change Skye's business and capital structure. The reverse split is a technical event that does not alter the company's fundamentals but is necessary to maintain its listing ahead of the Redx deal.
- The 1-for-8 reverse stock split will become effective at 12:01 am New York time on Thursday, August 24, 2026.
- Common stock will begin trading on a split-adjusted basis at market open on August 24, 2026, under the same ticker symbol SKYE.
- The new CUSIP number for the common stock following the reverse split is 83086J309.
- This filing is an amendment to the Original Form 8-K filed August 14, 2026, which disclosed the transaction agreement to acquire Redx Pharma Limited.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access